PII S0361-9230(99)00139-2
Mutations in the Tau gene cause
frontotemporal dementia
Bernardino Ghetti,
1
* Jill Murrell
1
and Maria Grazia Spillantini
2
1
Department of Pathology & Laboratory Medicine, Indiana University, Indianapolis, IN, USA; and
2
Department
of Neurology and Brain Repair Centre, University of Cambridge, Cambridge, UK
[Received 20 May 1999; Accepted 20 May 1999]
BACKGROUND
Deposits of intracellular filamentous material composed of micro-
tubule associated protein tau are present in numerous sporadic and
hereditary neurodegenerative diseases characterized by dementia.
Intraneuronal tau filaments are found in association with extracel-
lular deposition of amyloid- and prion protein amyloid as in
Alzheimer disease and in Gerstmann-Stra ¨ussler-Scheinker disease
Indiana kindred variant, respectively, while intracellular tau de-
posits may occur in neurons and glia in the absence of any other
abnormal protein deposition as in progressive supranuclear palsy,
corticobasal degeneration, and Pick disease. Knowledge of the
molecular pathology of Alzheimer disease in its sporadic and
hereditary forms has been extensively developed over the past two
decades; however, only recently has the focus been placed on
hereditary frontotemporal dementias. In 1994, our group identified
a form of familial frontotemporal dementia in which the presenting
signs were disequilibrium and paralysis of the vertical eye move-
ments [2]. A major neuropathologic characteristic was the filamen-
tous pathology made of hyperphosphorylated tau protein. The
presence of abnormal tau deposits in multiple regions of the brain,
in both neurons and glial cells, led us to call the disease in this
family Multiple System Tauopathy with Presenile Dementia
(MSTD) [7]. Since 1994, several autosomal-dominant forms of
similar disorders were linked to chromosome 17q21.2, the region
that contains the Tau gene [1,9]. Genetic linkage in MSTD re-
vealed that the gene responsible for the disease maps to chromo-
some 17q21.2 [5]. Thus, neuropathological findings and genetic
linkage studies showed the Tau gene a strong candidate for MSTD.
In 1996, following the clinical and genetic linkage assessment of
several hereditary forms of frontotemporal dementia at a consen-
sus conference, the name of frontotemporal dementia and Parkin-
sonism linked to chromosome 17 (FTDP-17) was chosen to char-
acterize a select group of familial dementias, including MSTD [1].
It was following this conference that the search for Tau gene
mutations became a priority.
HIGHLIGHT
In adult human brain, six tau isoforms are produced from a
single gene by alternative splicing. They differ from each other by
the presence or absence of 29- or 58-amino acid inserts located in
the amino-terminal half and a 31-amino acid repeat located in the
carboxy-terminal half. The latter, which is encoded by exon 10 of
the Tau gene, gives rise to the three four-repeat tau isoforms. The
repeats constitute the microtubule binding domains of tau.
We found that in MSTD, the tau deposits are characterized by
wide, twisted, ribbon-like filaments, which consist exclusively of
four-repeat tau isoforms, while the soluble tau contains a clear
preponderance of tau isoforms with four repeats over isoforms
with three repeats [7,8]. This observation led to the hypothesis that
a mutation might be present in the structure regulating the alter-
native splicing of tau exon 10. In June 1998, three papers [4,6,8],
including ours on MSTD, reported mutations in the Tau gene.
MSTD is caused by a G to A transition in the nucleotide adjacent
to the GT splice-donor site in the intron following exon 10, where
it destabilizes a predicted RNA stem loop.
Thus far, more than fifteen different mutations associated with
FTDP-17 have been found in the Tau gene. They are located in
exons 9, 10, 12, and 13 and in the intronic regions outside exons
9 and 10. Some of these mutations affect the ability of tau to bind
microtubules and others affect the splicing of exon 10 so that more
four-repeat tau is produced.
SIGNIFICANCE
The discovery of tau mutations is of fundamental importance
since it clearly shows that a primary lesion in tau causes nerve cell
degeneration. These findings will clarify the mechanisms leading
to filamentous tau pathology including that of Alzheimer disease.
In fact, at this time, the mutations in tau can be subdivided into
three groups according to the prevalence of tau isoforms present in
the inclusions and the morphology of the filaments. In the exon 10
mutations, the tau filaments contain mainly four-repeat isoforms
with only a small amount of three-repeat isoforms, in the intronic
mutations following exon 10, the tau filaments are composed of
four-repeat isoforms exclusively, and in the exon 12 and 13 mu-
tations, it is composed of all six isoforms.
The mechanism leading from a Tau gene mutation to nerve cell
degeneration is being elucidated; in fact, experimental studies in
vitro indicate that mutations cause a partial loss of tau function
resulting in microtubule destabilization and conceivably an alter-
ation of the axoplasmic transport [3]. It is also possible that the
* Address for correspondence: Prof. Bernardino Ghetti, Indiana University School of Medicine, Department of Pathology & Laboratory Medicine, 635
Barnhill Drive, MS A142, Indianapolis, IN 46202, USA. Fax: (317) 274-4882; E-mail: bghetti@iupui.edu
Brain Research Bulletin, Vol. 50, Nos. 5/6, pp. 471– 472, 1999
Copyright © 1999 Elsevier Science Inc.
Printed in the USA. All rights reserved
0361-9230/99/$–see front matter
471